Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Introduction Cancer immunotherapy, which harnesses patient's immune system to suppress and eliminate cancer cells, has emerged as a promising treatment [1], [2], [3]. However, its efficacy has been impeded by many hurdles, including the immunosuppressive tumor environment and inefficient stimulation of the immune system [4], [5].
Immune checkpoint blockade (ICB) has shown the high potential in treating various cancers [1], [2]. However, only a small number of patients profit from this treatment strategy [3]. The effectiveness of this strategy in other patients is hampered by the “cold” tumor characteristics of inferior immunogenicity and inadequate infiltration of T cells [4], [5], [6].
Oral Squamous Cell Carcinoma (OSCC) is a prevalent malignancy with a high rate of recurrence and metastasis, which are the primary reasons for its low five-year survival rate [1]. Despite significant advancements in early detection and treatment modalities, patients with OSCC often have poor prognoses owing to the aggressive nature of the disease and its propensity to metastasize [2].
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
